Compare SRRK & LYFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SRRK | LYFT |
|---|---|---|
| Founded | 2012 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.8B | 5.8B |
| IPO Year | 2018 | 2019 |
| Metric | SRRK | LYFT |
|---|---|---|
| Price | $47.49 | $15.73 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 29 |
| Target Price | ★ $56.17 | $20.07 |
| AVG Volume (30 Days) | 1.0M | ★ 11.2M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 11250.00 |
| EPS | N/A | ★ 0.04 |
| Revenue | N/A | ★ $6,316,261,000.00 |
| Revenue This Year | N/A | $17.33 |
| Revenue Next Year | $534.24 | $12.29 |
| P/E Ratio | ★ N/A | $396.50 |
| Revenue Growth | N/A | ★ 9.16 |
| 52 Week Low | $27.07 | $12.46 |
| 52 Week High | $58.49 | $25.54 |
| Indicator | SRRK | LYFT |
|---|---|---|
| Relative Strength Index (RSI) | 39.11 | 54.80 |
| Support Level | $45.83 | $12.93 |
| Resistance Level | $48.23 | $16.52 |
| Average True Range (ATR) | 2.20 | 0.67 |
| MACD | -0.65 | -0.02 |
| Stochastic Oscillator | 5.15 | 64.19 |
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.
Lyft is the second-largest ride-sharing service provider in the US and Canada, connecting riders and drivers over the Lyft app. Incorporated in 2013 and public since 2019, Lyft offers a variety of rides via private vehicles, including traditional private rides, shared rides, and luxury ones. Besides ride-share, Lyft has entered the bike- and scooter-share market to bring multimodal transportation options to users.